
Atorvastatin Hemicalcium Trihydrate by Zyntex is a high-purity crystalline form of the HMG-CoA reductase inhibitor (CAS 344423-98-9). It is a critical active pharmaceutical ingredient (API) used globally to lower cholesterol levels and prevent cardiovascular disease by inhibiting endogenous cholesterol synthesis in the liver.
Exceptional efficacy in reducing LDL-cholesterol and triglycerides provide a major advantage in preventative cardiology. Atorvastatin Hemicalcium Trihydrate works by increasing the number of LDL receptors on the surface of liver cells, making it a “gold standard” in the manufacturing of treatments for hypercholesterolemia. It helps patients significantly reduce the risk of myocardial infarction and stroke. For instance, it is a primary component in producing chronic maintenance therapy for patients with coronary heart disease. Consequently, it enhances long-term vascular health. As a result, Zyntex ensures precise control over moisture content and polymorphic purity for our supply. This ensures maximum stability and consistent dissolution profiles in your manufacturing cycles.
Moreover, Zyntex supplies high-grade Atorvastatin Hemicalcium Trihydrate for the pharmaceutical industry’s most rigorous applications. This compound acts as a critical agent in stabilizing atherosclerotic plaques. It pushes the boundaries of metabolic medicine by offering consistent systemic exposure. At the same time, it serves as a versatile active for combination products, often paired with other blood pressure or lipid-regulating agents. In short, our product serves as a dependable “cardiovascular life-cycle active.” It supports both the high-volume production needs of generic manufacturers and the stringent quality requirements of innovative medical research labs.
Recently, scientific interest in Atorvastatin Hemicalcium Trihydrate for its potential pleiotropic effects, including anti-inflammatory and antioxidant benefits in the vascular wall, has grown. It provides high efficacy in improving endothelial function. Because of this, Zyntex offers specialized micronized formats with verified chemical profiles to meet USP, EP, and IP pharmacopeia standards. These formats suit modern high-speed direct compression and granulation technology. Ultimately, choosing Zyntex secures a reliable and transparent pharmaceutical supply chain. We balance lipid-chemistry expertise with rigorous batch-to-batch HPLC and particle size monitoring. To conclude, our commitment ensures your manufacturing processes achieve the highest levels of performance and stability.
This essential lipid-regulating active is vital in these four sectors:
Primary API for cholesterol management and stroke prevention. Thus, it is a staple in heart disease treatment protocols.
Selected for its superior solid-state stability. Consequently, it is vital for ensuring long shelf-life in retail pharmaceutical products.
Used in clinical studies exploring the reversal of plaque buildup. Undoubtedly, it is essential for advanced atherosclerosis research.
Acts as a primary active in “polypill” formulations. Specifically, it supports the development of multi-target metabolic drugs.
| Parameter | Standard Value |
|---|---|
| Product Name | Atorvastatin Hemicalcium Trihydrate |
| Molecular Formula | $(C_{33}H_{34}FN_{2}O_{5})_{2}Ca \cdot 3H_{2}O$ |
| Molecular Weight | 1209.4 g/mol |
| CAS Number | 344423-98-9 |
⚠️ Safety & Handling: Atorvastatin Hemicalcium Trihydrate is a potent API and must be handled in a controlled pharmaceutical facility. Therefore, use adequate ventilation and wear appropriate PPE (mask, gloves, goggles) to prevent inhalation or skin contact. Not for direct sale to consumers. Store in a cool, dry place in tightly sealed containers, protected from light and heat to maintain its trihydrate stability.